| Year |
Citation |
Score |
| 2023 |
Chiasson-MacKenzie C, Vitte J, Liu CH, Wright EA, Flynn EA, Stott SL, Giovannini M, McClatchey AI. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nature Communications. 14: 1559. PMID 36944680 DOI: 10.1038/s41467-023-37226-0 |
0.343 |
|
| 2018 |
Chiasson-MacKenzie C, Morris ZS, Liu CH, Bradford WB, Koorman T, McClatchey AI. Merlin/ERM proteins regulate growth factor-induced macropinocytosis and receptor recycling by organizing the plasma membrane:cytoskeleton interface. Genes & Development. PMID 30143526 DOI: 10.1101/Gad.317354.118 |
0.675 |
|
| 2018 |
Benhamouche-Trouillet S, O'Loughlin E, Liu CH, Polacheck W, Fitamant J, McKee M, El-Bardeesy N, Chen CS, McClatchey AI. Proliferation-independent role of NF2 (merlin) in limiting biliary morphogenesis. Development (Cambridge, England). 145. PMID 29712669 DOI: 10.1242/Dev.162123 |
0.366 |
|
| 2018 |
Chiasson-MacKenzie C, McClatchey AI. EGFR-induced cytoskeletal changes drive complex cell behaviors: The tip of the iceberg. Science Signaling. 11. PMID 29382786 DOI: 10.1126/Scisignal.Aas9473 |
0.365 |
|
| 2017 |
Chiasson-MacKenzie C, McClatchey AI. Cell-Cell Contact and Receptor Tyrosine Kinase Signaling. Cold Spring Harbor Perspectives in Biology. PMID 28716887 DOI: 10.1101/Cshperspect.A029215 |
0.388 |
|
| 2015 |
Chiasson-MacKenzie C, Morris ZS, Baca Q, Morris B, Coker JK, Mirchev R, Jensen AE, Carey T, Stott SL, Golan DE, McClatchey AI. NF2/Merlin mediates contact-dependent inhibition of EGFR mobility and internalization via cortical actomyosin. The Journal of Cell Biology. 211: 391-405. PMID 26483553 DOI: 10.1083/Jcb.201503081 |
0.692 |
|
| 2014 |
Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, et al. Update from the 2013 International Neurofibromatosis Conference. American Journal of Medical Genetics. Part A. 164: 2969-78. PMID 25255738 DOI: 10.1002/Ajmg.A.36754 |
0.411 |
|
| 2014 |
McClatchey AI. ERM proteins at a glance. Journal of Cell Science. 127: 3199-204. PMID 24951115 DOI: 10.1242/Jcs.098343 |
0.475 |
|
| 2014 |
Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA. Merlin deficiency predicts FAK inhibitor sensitivity: A synthetic lethal relationship Science Translational Medicine. 6. PMID 24848258 DOI: 10.1126/Scitranslmed.3008639 |
0.418 |
|
| 2014 |
Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, ... ... McClatchey AI, et al. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. American Journal of Medical Genetics. Part A. 164: 563-78. PMID 24443315 DOI: 10.1002/Ajmg.A.36312 |
0.359 |
|
| 2013 |
Pore D, Parameswaran N, Matsui K, Stone MB, Saotome I, McClatchey AI, Veatch SL, Gupta N. Ezrin tunes the magnitude of humoral immunity. Journal of Immunology (Baltimore, Md. : 1950). 191: 4048-58. PMID 24043890 DOI: 10.4049/Jimmunol.1301315 |
0.389 |
|
| 2012 |
Hebert AM, DuBoff B, Casaletto JB, Gladden AB, McClatchey AI. Merlin/ERM proteins establish cortical asymmetry and centrosome position. Genes & Development. 26: 2709-23. PMID 23249734 DOI: 10.1101/Gad.194027.112 |
0.706 |
|
| 2012 |
McClatchey AI, Yap AS. Contact inhibition (of proliferation) redux. Current Opinion in Cell Biology. 24: 685-94. PMID 22835462 DOI: 10.1016/J.Ceb.2012.06.009 |
0.38 |
|
| 2012 |
McClatchey AI, Cichowski K. SPRED proteins provide a NF-ty link to Ras suppression. Genes & Development. 26: 1515-9. PMID 22802525 DOI: 10.1101/Gad.197434.112 |
0.343 |
|
| 2012 |
Casaletto JB, McClatchey AI. Spatial regulation of receptor tyrosine kinases in development and cancer. Nature Reviews. Cancer. 12: 387-400. PMID 22622641 DOI: 10.1038/Nrc3277 |
0.325 |
|
| 2012 |
Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. American Journal of Medical Genetics. Part A. 158: 24-41. PMID 22140088 DOI: 10.1002/Ajmg.A.34359 |
0.341 |
|
| 2011 |
Casaletto JB, Saotome I, Curto M, McClatchey AI. Ezrin-mediated apical integrity is required for intestinal homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 108: 11924-9. PMID 21730140 DOI: 10.1073/Pnas.1103418108 |
0.424 |
|
| 2011 |
Heiska L, Melikova M, Zhao F, Saotome I, McClatchey AI, Carpén O. Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment. Oncogene. 30: 4953-62. PMID 21666723 DOI: 10.1038/Onc.2011.207 |
0.411 |
|
| 2010 |
Gladden AB, Hebert AM, Schneeberger EE, McClatchey AI. The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Developmental Cell. 19: 727-39. PMID 21074722 DOI: 10.1016/J.Devcel.2010.10.008 |
0.722 |
|
| 2010 |
Shaffer MH, Huang Y, Corbo E, Wu GF, Velez M, Choi JK, Saotome I, Cannon JL, McClatchey AI, Sperling AI, Maltzman JS, Oliver PM, Bhandoola A, Laufer TM, Burkhardt JK. Ezrin is highly expressed in early thymocytes, but dispensable for T cell development in mice. Plos One. 5: e12404. PMID 20806059 DOI: 10.1371/Journal.Pone.0012404 |
0.361 |
|
| 2010 |
Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, McClatchey AI. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes & Development. 24: 1718-30. PMID 20675406 DOI: 10.1101/Gad.1938710 |
0.398 |
|
| 2010 |
Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Research. 70: 3483-93. PMID 20406973 DOI: 10.1158/0008-5472.Can-09-3107 |
0.383 |
|
| 2010 |
Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nature Reviews. Molecular Cell Biology. 11: 276-87. PMID 20308985 DOI: 10.1038/Nrm2866 |
0.472 |
|
| 2010 |
Fehon RG, McClatchey AI, Bretscher A. Erratum: Organizing the cell cortex: the role of ERM proteins Nature Reviews Molecular Cell Biology. 11: 674-674. DOI: 10.1038/Nrm2955 |
0.387 |
|
| 2009 |
Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, ... ... McClatchey A, et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5032-9. PMID 19671848 DOI: 10.1158/1078-0432.Ccr-08-3011 |
0.336 |
|
| 2009 |
Morris ZS, McClatchey AI. Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 106: 9767-72. PMID 19487675 DOI: 10.1073/Pnas.0902031106 |
0.649 |
|
| 2009 |
Morris ZS, McClatchey AI. The neurofibroma cell of origin: SKPs expand the playing field. Cell Stem Cell. 4: 371-2. PMID 19427284 DOI: 10.1016/J.Stem.2009.04.010 |
0.632 |
|
| 2009 |
McClatchey AI, Fehon RG. Merlin and the ERM proteins--regulators of receptor distribution and signaling at the cell cortex. Trends in Cell Biology. 19: 198-206. PMID 19345106 DOI: 10.1016/J.Tcb.2009.02.006 |
0.432 |
|
| 2009 |
Shaffer MH, Dupree RS, Zhu P, Saotome I, Schmidt RF, McClatchey AI, Freedman BD, Burkhardt JK. Ezrin and moesin function together to promote T cell activation. Journal of Immunology (Baltimore, Md. : 1950). 182: 1021-32. PMID 19124745 DOI: 10.4049/Jimmunol.182.2.1021 |
0.372 |
|
| 2008 |
Larsson J, Ohishi M, Garrison B, Aspling M, Janzen V, Adams GB, Curto M, McClatchey AI, Schipani E, Scadden DT. Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture. Cell Stem Cell. 3: 221-7. PMID 18682243 DOI: 10.1016/J.Stem.2008.06.005 |
0.363 |
|
| 2008 |
Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 111: 4716-22. PMID 18299447 DOI: 10.1182/Blood-2007-10-113068 |
0.405 |
|
| 2008 |
Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K. TORC1 is essential for NF1-associated malignancies. Current Biology : Cb. 18: 56-62. PMID 18164202 DOI: 10.1016/J.Cub.2007.11.066 |
0.42 |
|
| 2008 |
Cole BK, Curto M, Chan AW, McClatchey AI. Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Molecular and Cellular Biology. 28: 1274-84. PMID 18086884 DOI: 10.1128/Mcb.01139-07 |
0.747 |
|
| 2007 |
McClatchey AI. Neurofibromatosis. Annual Review of Pathology. 2: 191-216. PMID 18039098 DOI: 10.1146/annurev.pathol.2.010506.091940 |
0.317 |
|
| 2007 |
Curto M, McClatchey AI. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. British Journal of Cancer. 98: 256-62. PMID 17971776 DOI: 10.1038/Sj.Bjc.6604002 |
0.405 |
|
| 2007 |
Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. The Journal of Cell Biology. 177: 893-903. PMID 17548515 DOI: 10.1083/Jcb.200703010 |
0.751 |
|
| 2006 |
Bonilha VL, Rayborn ME, Saotome I, McClatchey AI, Hollyfield JG. Microvilli defects in retinas of ezrin knockout mice. Experimental Eye Research. 82: 720-9. PMID 16289046 DOI: 10.1016/J.Exer.2005.09.013 |
0.359 |
|
| 2005 |
McClatchey AI, Giovannini M. Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes & Development. 19: 2265-77. PMID 16204178 DOI: 10.1101/Gad.1335605 |
0.543 |
|
| 2005 |
Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR. A mouse model recapitulating molecular features of human mesothelioma. Cancer Research. 65: 8090-5. PMID 16166281 DOI: 10.1158/0008-5472.Can-05-2312 |
0.385 |
|
| 2004 |
Saotome I, Curto M, McClatchey AI. Ezrin is essential for epithelial organization and villus morphogenesis in the developing intestine. Developmental Cell. 6: 855-64. PMID 15177033 DOI: 10.1016/J.Devcel.2004.05.007 |
0.44 |
|
| 2004 |
Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, ... ... McClatchey AI, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Research. 64: 3718-24. PMID 15150133 DOI: 10.1158/0008-5472.Can-03-4079 |
0.346 |
|
| 2004 |
Curto M, McClatchey AI. Ezrin...a metastatic detERMinant? Cancer Cell. 5: 113-4. PMID 14998486 DOI: 10.1016/S1535-6108(04)00031-5 |
0.376 |
|
| 2003 |
McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer development? Nature Reviews. Cancer. 3: 877-83. PMID 14668818 DOI: 10.1038/Nrc1213 |
0.336 |
|
| 2003 |
Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes & Development. 17: 1090-100. PMID 12695331 DOI: 10.1101/Gad.1054603 |
0.536 |
|
| 2003 |
Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber DA. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell. 112: 673-84. PMID 12628187 DOI: 10.1016/S0092-8674(03)00155-7 |
0.417 |
|
| 2002 |
Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene. 21: 7453-63. PMID 12386807 DOI: 10.1038/Sj.Onc.1205936 |
0.356 |
|
| 2001 |
Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AI. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Developmental Cell. 1: 63-72. PMID 11703924 DOI: 10.1016/S1534-5807(01)00009-0 |
0.48 |
|
| 1998 |
McClatchey AI, Jacks T. Tumor suppressor mutations in mice: the next generation. Current Opinion in Genetics & Development. 8: 304-10. PMID 9690995 DOI: 10.1016/S0959-437X(98)80086-5 |
0.346 |
|
| 1998 |
McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, Jacks T. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes & Development. 12: 1121-33. PMID 9553042 DOI: 10.1101/Gad.12.8.1121 |
0.46 |
|
| 1998 |
Shaw RJ, McClatchey AI, Jacks T. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. The Journal of Biological Chemistry. 273: 7757-64. PMID 9516485 DOI: 10.1074/Jbc.273.13.7757 |
0.495 |
|
| 1997 |
McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes & Development. 11: 1253-65. PMID 9171370 DOI: 10.1101/Gad.11.10.1253 |
0.471 |
|
| 1994 |
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science (New York, N.Y.). 266: 807-10. PMID 7973635 DOI: 10.1126/Science.7973635 |
0.353 |
|
| Show low-probability matches. |